Alliances
Cooperation focused on the joint development and optimization of human anti-infective drug candidates against gram-negative and gram-positive bacteria in relevant indications using Lysando’s Artilysin®s technology platform
Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.
Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.
Gilead is paying Lyndra $15 million upfront to develop a formulation for HIV that can be taken once a week, as opposed to every day.
Vivoryon Therapeutics AG and MorphoSys AG today announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon’s small molecule QPCTL inhibitors in the field of oncology.
Collaboration prioritizes scientific innovation and social change to one day eliminate lung cancer as a cause of death
Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area.
Skyhawk and Merck will partner to discover and develop innovative RNA-binding small molecules that can form treatments for neurological diseases and cancer.
Anahit International Corp. has licensed a patent from the University of Guelph to biosynthesize Cannflavin A and B outside of the cannabis plant.
Nosopharm and Evotec SE announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.
PRESS RELEASES